Real-world clinical analysis of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer complicated by chronic obstructive pulmonary disease
10.12354/j.issn.1000-8179.2025.20250189
- VernacularTitle:非小细胞肺癌合并慢性阻塞性肺疾病患者免疫检查点抑制剂治疗的真实世界临床分析
- Author:
Zhao CAN
1
;
Song LIPING
1
;
Xiang PINGCHAO
1
Author Information
1. 北京大学首钢医院呼吸与危重症医学科(北京市 100144)
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer(NLCLC);
chronic obstructive pulmonary disease(COPD);
immune checkpoint inhibitors(ICIs);
ef-ficacy;
adverse reactions
- From:
Chinese Journal of Clinical Oncology
2025;52(7):345-353
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy,safety,and prognostic factors associated with immune checkpoint inhibitors(ICIs)in pa-tients with non-small cell lung cancer(NSCLC)comorbid with chronic obstructive pulmonary disease(COPD).Methods:Clinical and patholo-gical data were collected from 100 patients with stage Ⅲ-Ⅳ NSCLC who received one or more cycles of ICI treatment at Peking University Shougang Hospital between January 2018 and October 2024 were collected.Based on COPD diagnosis,patients were assigned into the NSCLC with COPD(LC-COPD,n=52)and NSCLC without COPD(non-COPD,n=48)groups.The efficacy,safety,and prognostic factors of ICIs treatment were retrospectively analyzed in both groups.Survival analysis was performed using the Kaplan-Meier method,and survival rates were compared using the Log-rank test.Results:Among the patients who received ICIs treatment,median progression-free survival(PFS)in the LC-COPD group was longer than that in the non-COPD group(11.97 vs.7.83 months,P=0.022),but no significant difference was detec-ted in overall survival(OS)(22.37 vs.16.80 months,P=0.110).Compared with the LC-COPD group and patients with normal lung function,the preserved ratio impaired spirometry(PRISm)subgroup showed worse median PFS and OS following immunotherapy(all P<0.05).Multivari-ate analysis revealed that COPD comorbidity,programmed cell death-ligand 1(PD-L1)expression,treatment line,and neutrophil to lympho-cyte ratio(NLR)were independently associated with PFS(P<0.05).Additionally,PD-L1 expression,immunotherapy efficacy,NLR,and inhaled corticosteroids(ICS)use were significantly associated with OS(P<0.05).The incidence of immune-related adverse events was comparable between the two groups.Conclusions:ICI treatment demonstrated a greater positive impact on PFS in patients with NSCLC and COPD than in patients with NSCLC alone in a real-world study,with a good safety profile in both groups.NSCLC patients with PRISm showed poorer out-comes following ICI treatment.PD-L1 expression,FeNO,NLR,and ICS may serve as potential predictive biomarkers for immunotherapy effic-acy in NSCLC patients with COPD.
